Amgen's Repatha Shows Efficacy in Primary Prevention, Yet Broader Risks Keep Thesis Cautious

What happened

Amgen announced that Repatha reduced the risk of first major cardiovascular events by 31% in high-risk primary prevention patients without known significant atherosclerosis, based on a VESALIUS-CV subgroup analysis. This finding supports earlier initiation of the drug and expands its potential market beyond secondary prevention, reinforcing its role as a key growth asset. However, the DeepValue report indicates that Repatha must offset steep declines in legacy products like ENBREL and Otezla, which are facing 30-38% net price drops due to IRA policies and biosimilar competition. The stock trades at a premium valuation of ~23.7x P/E, embedding expectations for sustained growth while grappling with elevated leverage, unresolved tax risks, and dependency on the obesity drug MariTide. Thus, while this news is positive, it does not fundamentally alter the near-term risk-reward skew, which remains negative due to policy headwinds and pipeline uncertainties.

Implication

This efficacy update could enhance Repatha's market penetration in primary prevention, supporting incremental revenue growth. However, that growth must counter accelerating erosion in mature franchises, where ENBREL and Otezla face ongoing price compression. Amgen's high valuation leaves limited buffer for execution missteps, especially with key catalysts like MariTide Phase 3 data still ahead. The news does not address structural risks such as tax exposures or leverage, which could strain the balance sheet. Consequently, investors should see this as a reinforcement of Repatha's importance but not a catalyst to change the cautious stance, preferring entry points below $295 for better risk-reward.

Thesis delta

The new Repatha data provides a slight upside to growth estimates but does not shift the core investment thesis, which remains a 'POTENTIAL SELL'. Repatha's expanded indication may support base-case valuation, yet asymmetric risks from policy pressures and pipeline dependencies continue to overshadow near-term positives. Therefore, no material change in thesis is warranted; the stock still requires a pullback to offer an attractive entry.